Arrowhead Pharma Q3 2024 GAAP EPS $(1.38) Misses $(0.53) Estimate
Portfolio Pulse from Benzinga Newsdesk
Arrowhead Pharma (NASDAQ:ARWR) reported a Q3 2024 GAAP EPS of $(1.38), significantly missing the analyst consensus estimate of $(0.53) by 160.38%.
August 08, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Arrowhead Pharma reported a Q3 2024 GAAP EPS of $(1.38), missing the analyst consensus estimate of $(0.53) by 160.38%. This significant earnings miss is likely to negatively impact the stock price in the short term.
The substantial earnings miss indicates weaker-than-expected financial performance, which is likely to result in a negative market reaction and a decline in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100